GSK Extends Shingrix Collaboration with Zhifei in China, Explores RSV Vaccine Partnership

Extended Collaboration:
GSK and Chongqing Zhifei Biological Products have revised and extended their strategic vaccine collaboration in China for GSK's shingles vaccine, Shingrix, through 20341 3 5.

Reduced Deliveries:
The revised agreement reduces the minimum purchase levels for Shingrix, with a potential total value to GSK of GBP 2.3 billion over the 6-year period from 2024 to 20291 3 5.

RSV Vaccine Partnership:
Zhifei has agreed to exclusively engage with GSK to explore a potential collaboration on the commercialization of GSK's respiratory syncytial virus (RSV) vaccine, Arexvy, in mainland China for an initial term of 10 years, subject to regulatory approval1 3 5.

Arexvy Efficacy:
GSK's RSV vaccine, Arexvy, has shown clinically meaningful efficacy over three full RSV seasons, with a cumulative efficacy of 62.9% against RSV-LRTD and 67.4% against severe RSV-LRTD2.

Regulatory Approvals:
Arexvy has been approved in the US and EU for the prevention of RSV-LRTD in individuals 60 years of age and older, and in the US and EU for use in individuals aged 50-59 who are at increased risk due to certain underlying medical conditions2 4.